Biguanides Global Market Report 2026

Biguanides are a class of drugs mainly prescribed for type 2 diabetes treatment. They reduce blood sugar by decreasing hepatic glucose production and enhancing insulin sensitivity. These drugs also manage polycystic ovary syndrome (PCOS) and various metabolic conditions.

The primary biguanides include metformin, phenformin, and several others. Metformin stands out as a commonly prescribed biguanide drug for managing type 2 diabetes by reducing blood glucose levels. It comes in multiple dosage forms, such as tablets and oral solutions, available in options like immediate-release and extended-release, and is distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have affected the biguanides market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), leading to higher production costs and potential delays in supply chains. Regions like Asia-Pacific, which are major manufacturing hubs for biguanides, are most impacted, particularly for metformin and extended-release formulations. Hospital and retail pharmacy segments may face temporary price increases, while local manufacturers might benefit from protective measures, encouraging domestic production and reducing dependency on imports. Overall, the tariffs have a mixed impact, creating challenges in cost management but potential incentives for local manufacturing.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $5.11 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, rising awareness of metabolic disorders, growth in generic biguanides availability, adoption of oral antidiabetic medications, advancements in liver-targeted therapies.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.97 billion in 2030 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, expansion of telemedicine for diabetes care, rising incidence of pcOS, development of combination therapies, government initiatives promoting chronic disease management. Major trends in the forecast period include personalized diabetes management solutions, combination therapy development, expanded indications beyond type 2 diabetes, home healthcare & remote patient monitoring, cost-effective generic biguanides.

The increasing prevalence of diabetes is anticipated to drive expansion in the biguanides market. Diabetes represents a chronic metabolic condition marked by high blood glucose levels resulting from inadequate insulin production or ineffective insulin action. This surge in diabetes stems from shifts in lifestyle, an aging population, and greater awareness through diagnostics. Biguanides aid in managing diabetes by enhancing insulin sensitivity, curbing glucose output from the liver, and assisting in blood sugar reduction for those with type 2 diabetes. For instance, in March 2024, data from the Office for Health Improvement & Disparities (OHID), a UK government body, showed that from March 2022 to March 2023, the share of type 1 diabetes patients completing all eight recommended care processes rose by 22%, with a 21% increase for type 2 diabetes, and the percentage meeting target HbA1c levels hit 37.9%-the highest on record. Thus, the growing incidence of diabetes is fueling biguanides market growth.

Major companies in the biguanide market are prioritizing the development of innovative solutions like extended-release biguanide formulations to boost patient compliance, optimize glycemic control, and reduce gastrointestinal side effects. Extended-release biguanide formulations are medications engineered to release their active ingredient slowly over time, ensuring steady blood levels, better tolerability, and stronger long-term adherence for people managing diabetes. For example, in August 2023, Dr. Reddy's Laboratories, an India-based biotech firm, introduced saxagliptin and metformin hydrochloride extended-release tablets-a USFDA-approved generic equivalent of KOMBIGLYZE XR that pairs saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide-providing adults with type 2 diabetes a convenient once-daily option that aids glycemic control alongside diet and exercise, while its extended-release mechanism promotes greater adherence.

In August 2023, Lupin, an India-based biopharmaceutical firm, purchased the diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This deal bolsters Lupin's standing in the anti-diabetes market by broadening its lineup with proven oral antidiabetic treatments. It also boosts the company's capacity to enhance patient access to vital diabetes drugs and solidifies its rivalry in the metabolic disorders sector. Boehringer Ingelheim, a Germany-based biopharmaceutical firm, focuses on researching, developing, and manufacturing therapies for human and veterinary use.

Major companies operating in the biguanides market are Pfizer Inc., Sanofi-Aventis LLC, Viatris Inc., Aurobindo Pharma Ltd., Cipla Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories

Asia-Pacific was the largest region in the biguanides market in 2025. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Metformin; Phenformin; Other Types
• 2) By Dosage Form: Tablets; Oral Solutions
• 3) By Formulation: Immediate Release; Extended Release
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
• 2) By Phenformin: Phenformin Hydrochloride
• 3) By Other Types: Buformin; Metformin Combinations
• Companies Mentioned: Pfizer Inc.; Sanofi-Aventis LLC; Viatris Inc.; Aurobindo Pharma Ltd.; Cipla Ltd; Dr. Reddy's Laboratories; Lupin Limited; Zydus Lifesciences Limited; Torrent Pharmaceuticals Limited; Intas Pharmaceuticals Ltd.; Apotex Inc; Sun Pharmaceutical Industries Ltd.; Glenmark Pharmaceuticals Ltd.; Mylan Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Alkem Laboratories Ltd.; Panacea Biotech Ltd.; Wanbury Ltd; USV Private Limited; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.